Carson Kenum
YOU?
Author Swipe
View article: Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer
Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer Open
Effective treatment for metastatic cancer has remained elusive due to the persistence of drug-resistant metastasis stem cells (MetSCs) that drive relapse. MetSCs are tumor cell subpopulations enriched for their ability to reinitiate and su…
View article: L1CAM signaling through planar cell polarity generates SOX2<sup>+</sup> metastatic progenitors in lung adenocarcinoma
L1CAM signaling through planar cell polarity generates SOX2<sup>+</sup> metastatic progenitors in lung adenocarcinoma Open
Plasticity transitions during carcinoma progression generate fetal-like progenitor states with metastatic capacity. How these progenitors emerge and persist during tumor progression remains unknown. Here, we elucidate a process that drives…
View article: Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma
Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma Open
Neuroblastoma (NB) is a predominantly pediatric cancer with greater than 90% of cases arising in children under the age of five. More than half of patients have metastases detected at diagnosis, and high-risk disease is associated with fiv…
View article: Argonaute 2 modulates EGFR–RAS signaling to promote mutant<i>HRAS</i>and<i>NRAS-</i>driven malignancies
Argonaute 2 modulates EGFR–RAS signaling to promote mutant<i>HRAS</i>and<i>NRAS-</i>driven malignancies Open
Activating mutations in RAS GTPases drive nearly 30% of all human cancers. Our prior work described an essential role for Argonaute 2 (AGO2), of the RNA-induced silencing complex, in mutant KRAS-driven cancers. Here, we identified a novel …
View article: Biochemical characterization of the interaction between KRAS and Argonaute 2
Biochemical characterization of the interaction between KRAS and Argonaute 2 Open
Oncogenic mutations in KRAS result in a constitutively active, GTP-bound form that in turn activates many proliferative pathways. However, because of its compact and simple architecture, directly targeting KRAS with small molecule drugs ha…
View article: AGO2 promotes tumor progression in KRAS-driven mouse models of non–small cell lung cancer
AGO2 promotes tumor progression in KRAS-driven mouse models of non–small cell lung cancer Open
Significance RAS proteins (HRAS, NRAS, and KRAS) integrate extracellular trophic signals to promote cell proliferation. Constitutively active KRAS drives tumor initiation and progression in nonsmall cell lung cancer (NSCLC). As RAS protein…